Safety Incidents OSHA Severe Injury Reports · 2015–2025
5,189,214Inspections Most recent open 2026-07-16 Last loaded 2026-07-20

OSHA Inspection: ROCHE BIOMEDICAL LABORATORIES, INC.

Complaint inspection · Health discipline

On , OSHA opened a complaint health inspection of ROCHE BIOMEDICAL LABORATORIES, INC. in 245 SUMMIT POINT DRIVE, HENRIETTA, NY 14467 (NAICS 000000). OSHA activity number 106886757.

Watch Roche Biomedical Laboratories, INC. — free Get an email when a new federal OSHA severe-injury report for Roche Biomedical Laboratories, INC. is published. One employer, no account, unsubscribe in one click.
Site address
245 SUMMIT POINT DRIVE
City
HENRIETTA
State
NY
ZIP
14467
Inspection type
Complaint (B)
Scope
Partial (B)
Discipline
Health
Advance notice
No
Union status
B
Opened
Closing conference
Case closed
Data loaded
NAICS code
000000
SIC code (legacy)
8071
Employees
31
Ownership type
A

4 citations on file for this inspection.

5(a)(1)

Serious Gravity 08 1 instance 12 exposed
Issued
Abate by
Penalty
Initial $640.00 · Current $640.00
Section 5(a)(1) of the Occupational Safety and Health Act of 1970: The
employer did not furnish employment and a place of employment which were
free from recognized hazards that were causing or likely to cause death
or serious physical harm to employees in that employees were exposed to
blood and body fluids potentially infected with Hepatitis B Virus (HBV)
and/or Human Immunodeficiency Virus (HIV):
a) Throughout establishment, on or about 12/4/90. Laboratory technicians
were exposed to blood and body fluids while performing daily work
practices, such as transferring, pipetting, and preparing slides
of blood and/or body fluids in that several employees had not
received Hepatitis B vaccinations.
The hazards of such exposure include, but are not limited to, the
onset of clinical symptoms of acute Hepatitis B, anorexia, abdominal
pain, jaundice, and the potential for becoming a chronic carrier of
the Hepatitis B and/or Human Immunodeficiency Virus.
Among other methods, one feasible abatement method to reduce this hazard
is to establish and enforce adequate procedures regarding exposure to
and handling of blood and body fluids, such as those stipulated by the
Centers for Disease Control (CDC) Guidelines published in Morbidity and
Mortality Weekly Report, June 24, 1988, Volume 37, Number 24. Elements
essential to an Infection Control Program include at a minimum:
Hepatitis B Vaccination. The facility's infection control policy
regarding Hepatitis B vaccinations shall address all circumstances
warranting such vaccinations and shall identify employees at
substantial risk of directly contacting body fluids. All such
employees shall be offered Hepatitis B vaccinations free of charge
in amounts and at times prescribed by standard medical practices.
Recent events (2)
  • — R (S) $640.00
  • — Z (S) $640.00

1910.145 F08 I

Serious Gravity 08 2 instances 12 exposed
Issued
Abate by
Penalty
Initial $640.00 · Current $200.00 Reduced
Recent events (2)
  • — R (S) $200.00
  • — Z (S) $640.00

1910.1450 F01

Serious Gravity 07 1 instance 12 exposed
Issued
Abate by
Penalty
Initial $420.00 · Current $200.00 Reduced
Recent events (2)
  • — R (S) $200.00
  • — Z (S) $420.00

1904.2 A

Other-than-serious Gravity 02 2 instances 31 exposed
Issued
Abate by

View ROCHE BIOMEDICAL LABORATORIES, INC.'s full OSHA safety record →

KGC, INC.

This record is reproduced from the U.S. Department of Labor Open Data API (OSHA inspection dataset). The original IMIS detail view is available at OSHA's Establishment Search for activity number 106886757.